119 related articles for article (PubMed ID: 31815146)
1. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Canivell S; Mata-Cases M; Vlacho B; Gratacòs M; Real J; Mauricio D; Franch-Nadal J
J Diabetes Res; 2019; 2019():2018374. PubMed ID: 31815146
[TBL] [Abstract][Full Text] [Related]
2. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
3. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.
Pasternak B; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Ueda P
BMJ; 2020 Apr; 369():m1186. PubMed ID: 32349963
[TBL] [Abstract][Full Text] [Related]
4. The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice.
Vercalsteren E; Karampatsi D; Buizza C; Nyström T; Klein T; Paul G; Patrone C; Darsalia V
Cardiovasc Diabetol; 2024 Feb; 23(1):88. PubMed ID: 38424560
[TBL] [Abstract][Full Text] [Related]
5. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
Sen T; Ju W; Nair V; Ladd P; Menon R; Otto EA; Pyle L; Vigers T; Nelson RG; Arnott C; Neal B; Hansen MK; Kretzler M; Bjornstad P; Heerspink HJL
Kidney Int; 2023 Oct; 104(4):828-839. PubMed ID: 37543256
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Sodium-Glucose Co-Transporter 2 Inhibitor Kidney Outcome Trial Participants with a Real-World Chronic Kidney Disease Primary Care Population.
Forbes AK; Hinton W; Feher MD; Elson W; Ordóñez-Mena JM; Joy M; Fan X; Banerjee D; Cole NI; Munro N; Whyte M; Suckling RJ; Swift PA; de Lusignan S
Nephrol Dial Transplant; 2024 Mar; ():. PubMed ID: 38520170
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.
Schernthaner G; Jarvis S; Lotan C; Prázný M; Wanner C; Wascher TC
Ther Clin Risk Manag; 2017; 13():69-79. PubMed ID: 28144148
[TBL] [Abstract][Full Text] [Related]
8. Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).
Schernthaner G; Khunti K; Lotan C; Burnier M; Drexel H; Prázný M
Ther Clin Risk Manag; 2017; 13():1569-1576. PubMed ID: 29276388
[TBL] [Abstract][Full Text] [Related]
9. Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial).
Aoki Y; Hamrén B; Clegg LE; Stahre C; Bhatt DL; Raz I; Scirica BM; Oscarsson J; Carlsson B
PLoS One; 2021; 16(11):e0259372. PubMed ID: 34797832
[TBL] [Abstract][Full Text] [Related]
10. Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes.
Bragagni A; Piani F; Borghi C
Eur Heart J Suppl; 2021 Oct; 23(Suppl E):E40-E44. PubMed ID: 34650352
[TBL] [Abstract][Full Text] [Related]
11. Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).
Schernthaner G; Lehmann R; Prázný M; Czupryniak L; Ducena K; Fasching P; Janež A; Karasik A; Kempler P; Martinka E; Shestakova MV; Duvnjak LS; Tankova T
Cardiovasc Diabetol; 2017 Oct; 16(1):137. PubMed ID: 29061170
[TBL] [Abstract][Full Text] [Related]
12. PDM-ProValue meets cardiovascular outcome trials in diabetes.
Fritzen K; Schnell O
Cardiovasc Diabetol; 2019 Jan; 18(1):10. PubMed ID: 30691463
[TBL] [Abstract][Full Text] [Related]
13. Representativeness of Participants in the ACCORD Trial Compared to Middle-aged and Older Adults Living with Diabetes in the United States.
Ikesu R; Wu Y; Zimmerman SC; Inoue K; Buto P; Power MC; Schaefer CA; Glymour MM; Mayeda ER
Epidemiology; 2024 Jul; 35(4):432-436. PubMed ID: 38771709
[TBL] [Abstract][Full Text] [Related]
14. The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care.
Russo G; Di Bartolo P; Candido R; Lucisano G; Manicardi V; Giandalia A; Nicolucci A; Rocca A; Rossi MC; Di Cianni G;
Diabetes Res Clin Pract; 2023 May; 199():110672. PubMed ID: 37084893
[TBL] [Abstract][Full Text] [Related]
15. Polygenic subtype identified in ACCORD trial displays a favorable type 2 diabetes phenotype in the UKBiobank population.
Hershberger C; Mariam A; Pantalone KM; Buse JB; Motsinger-Reif AA; Rotroff DM
Hum Genomics; 2024 Jun; 18(1):70. PubMed ID: 38909264
[TBL] [Abstract][Full Text] [Related]
16. Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs.
Maranta F; Cianfanelli L; Regoni M; Cianflone D
Int J Cardiol Heart Vasc; 2018 Dec; 21():80-86. PubMed ID: 30402533
[TBL] [Abstract][Full Text] [Related]
17. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
18. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
[TBL] [Abstract][Full Text] [Related]
19. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
[TBL] [Abstract][Full Text] [Related]
20. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Bhatt DL; Szarek M; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Verma S; Lapuerta P; Pitt B;
N Engl J Med; 2021 Jan; 384(2):117-128. PubMed ID: 33200892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
